Accelerate Diagnostics, Inc. - AXDX Enterprise Value-to-Revenue Multiple

acceleratediagnostics.com (AXDX) - corporate logo

Leadership in Pheno bacteria analysis automation with AI screening is driving the stock dynamics for Accelerate Diagnostics (AXDX). The EV/Sales valuation multiple demonstrates the impact of this innovation, where the mark reflects the latest data. Success is based on a strong team of microbiologists with RSU incentives; however, a liquidity deficit and slow system implementation in clinics create financial risks for Accelerate Diagnostics (AXDX).

Accelerate Diagnostics, Inc. (AXDX) - EV/Sales Multiple from 07/04/2022 to 11/19/2026

Accelerate Diagnostics Inc. - analytical breakdowns and key metrics (AXDX)

Fundamental valuation:Accelerate Diagnostics (AXDX)
Product sample of Accelerate Diagnostics, Inc.

For the investor, positions in Accelerate Diagnostics (AXDX) are determined by the expansion rate of pathogen identification systems in clinics while maintaining financial stability. The metric reflects the enterprise value (EV) to revenue ratio, neutralizing the impact of debt for an objective comparison of sales generation efficiency. When analyzing the current valuation of the company relative to revenue, it should be compared with equipment implementation cycles to distinguish market leadership from inflated expectations.

Competitor analysis for Accelerate Diagnostics

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Exagen - Company Value to Revenue Ratio|EV/Sales Multiple MDXH (MDxHealth, Inc.)|luciddx.com (LUCD) - Enterprise Value-to-Revenue Multiple|prenetics.com - EV/Sales Multiple|Insight Molecular Diagnostics, Inc. (IMDX) - Company Value to Revenue|TRIB: EV/Sales Multiple|ProPhase - Business Value to Revenue|Enterprise Value-to-Revenue Ratio ainos.com|CODX: Business Value to Revenue|Enterprise Value-to-Revenue Ratio HeartSciences (HSCS)|Company Value to Revenue Biomerica Inc. BMRA|EV/Sales Multiple CDIO (Cardio Diagnostics)|ONCO - Company Value to Revenue|VRAX: Company Value to Revenue|bluejaydx.com (BJDX) - Company Value to Revenue|AWH: EV/Sales Multiple|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue